Company intelligence / Profile preview

Tachmed

London, England, United Kingdomtachmed.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Tachmed has developed a digital health toolbox centered on a smart health meter that uses graphene biosensors to capture disease biomarkers. The device enables rapid at-home self-testing with instant electronic reporting to clinicians. AI is used to accelerate assay development and expand the test menu. Clinical launch in the US was planned for spring 2024, with further rollouts anticipated in other regions.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: DeviceDigital diagnostic platformBiosensor-based diagnostics (graphene biosensors)
Industry: Protein Biomarker Diagnostics

Partnerships

City St George’s University of London (assay development collaboration)Daemon (AI-driven product development partnership)

Beyond the preview

Go deeper on Tachmed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tachmed.

Explore the full profile